The acquisition of the US software publisher for clinical trial monitoring is by far the largest operation in the group's history.

Dassault Systems announced today that it has purchased Nasdaq-listed USD 5.8 billion Nasdaq-listed software publisher Medidata, which is by far the largest transaction in Dassault Systems.

The French publisher of industrial software said in a statement to have offered 92.25 dollars per share, in a transaction approved unanimously by the two boards of directors and will be finalized in the last quarter of 2019.

"This is the first time an acquisition of the group exceeds one billion," said Pascal Daloz, Deputy General Manager of Dassault Systèmes in a conference call. "Medidata's leadership in clinical trials perfectly complements our solutions in the life sciences field," he said. Medidata "really represents an expansion of our offer".

Dassault Systèmes is already committed to collaborating with the world's top 20 biopharmaceutical companies, hundreds of biotechnology companies, medical device manufacturers, research institutes, and government regulators "to develop and market products and technologies. innovative health care ".

Founded in 1999, Medidata had a 2018 turnover of USD 636 million and 2,800 employees.

"Our mission to deliver the best targeted treatment at the right time to every patient has fueled our 20-year history of innovation and engagement in the life science industry," commented Tarek Sherif, co-founder and chief executive officer of Medidata, quoted in the statement.

Dassault Systems posted very good results in the first quarter this year, with a net profit up 18% driven by its flagship product, the 3DExperience platform. This platform enables end-to-end industrial project management, from design to simulation of production and definition of industrial organization.


Source: Le Figaro - AFP - 13th June 2019